Molecule AI

"𝐌𝐨𝐥𝐞𝐜𝐮𝐥𝐞 𝐀𝐈: 𝐍𝐨𝐯𝐞𝐦𝐛𝐞𝐫 𝐍𝐞𝐰𝐬𝐥𝐞𝐭𝐭𝐞𝐫 – 𝐈𝐧𝐭𝐞𝐥𝐥𝐢𝐠𝐞𝐧𝐭 𝐀𝐮𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐁𝐢𝐨𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 🚀 This month, we delve into the transformative impact of AI, robotics, and deep tech on sustainable biomanufacturing. Key highlights include: 1. AI-powered iBioFoundries reshaping innovation in protein and cellular engineering. 2. Amgen’s cutting-edge biomanufacturing facility featuring advanced AI and automation. 3. Pow.Bio’s revolutionary AI-controlled fermentation platform driving productivity gains. 4. OmniaBio’s AI-enabled cell and gene therapy manufacturing hub in Canada. 5. Strategic collaborations like Sartorius and NVIDIA advancing digital biomanufacturing. At Molecule AI, we’re committed to exploring how these technologies can shape the future of biopharma by enhancing efficiency, scalability, and sustainability. #MoleculeAI #NovemberNewsletter #Biomanufacturing #AI #DigitalTransformation #Innovation

𝐏𝐫𝐨𝐟𝐞𝐬𝐬𝐨𝐫 M Balakrishnan Honored with 𝐊𝐧𝐨𝐰𝐃𝐢𝐬 𝐀𝐰𝐚𝐫𝐝 𝐟𝐨𝐫 𝐄𝐱𝐜𝐞𝐥𝐥𝐞𝐧𝐜𝐞 2024 We are delighted to share that 𝐏𝐫𝐨𝐟𝐞𝐬𝐬𝐨𝐫 𝐌. 𝐁𝐚𝐥𝐚𝐤𝐫𝐢𝐬𝐡𝐧𝐚𝐧 has received the esteemed 𝐊𝐧𝐨𝐰𝐃𝐢𝐬 𝐀𝐰𝐚𝐫𝐝 𝐟𝐨𝐫 𝐄𝐱𝐜𝐞𝐥𝐥𝐞𝐧𝐜𝐞 2024, recognizing his transformative contributions to academia, research, and assistive technology. Professor Balakrishnan, a pioneering force in computer science and engineering, has left a lasting legacy at Indian Institute of Technology, Delhi and continues to inspire as a 𝐃𝐢𝐬𝐭𝐢𝐧𝐠𝐮𝐢𝐬𝐡𝐞𝐝 𝐕𝐢𝐬𝐢𝐭𝐢𝐧𝐠 𝐏𝐫𝐨𝐟𝐞𝐬𝐬𝐨𝐫 𝐚𝐭 𝐏𝐥𝐚𝐤𝐬𝐡𝐚 𝐔𝐧𝐢𝐯𝐞𝐫𝐬𝐢𝐭𝐲. His innovative work at the 𝐀𝐒𝐒𝐈𝐒𝐓𝐄𝐂𝐇 𝐋𝐚𝐛, focused on assistive technologies for 𝐬𝐨𝐜𝐢𝐚𝐥 𝐠𝐨𝐨𝐝, underscores his commitment to leveraging technology for impactful change. The achievement has been featured by ANI News (https://lnkd.in/gFajzdZ2), with coverage also appearing in ThePrint and Google News. The award ceremony at Indian Institute of Technology, Delhi brought together faculty, alumni, and industry leaders in a heartfelt celebration of his remarkable journey. Congratulations to Professor Balakrishnan on this well-deserved honor! #computerscience #machinelearning #media #award #artificialintelligence

𝐓𝐡𝐫𝐢𝐥𝐥𝐞𝐝 𝐭𝐨 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞 𝐎𝐮𝐫 𝐏𝐚𝐩𝐞𝐫 𝐀𝐜𝐜𝐞𝐩𝐭𝐚𝐧𝐜𝐞 𝐚𝐭 𝐊𝐃𝐃 2025! https://lnkd.in/gt9rJKA7 We are excited to share that our paper, "𝐀 𝐅𝐫𝐚𝐦𝐞𝐰𝐨𝐫𝐤 𝐟𝐨𝐫 𝐋𝐞𝐯𝐞𝐫𝐚𝐠𝐢𝐧𝐠 𝐏𝐚𝐫𝐭𝐢𝐚𝐥𝐥𝐲-𝐋𝐚𝐛𝐞𝐥𝐞𝐝 𝐃𝐚𝐭𝐚 𝐟𝐨𝐫 𝐏𝐫𝐨𝐝𝐮𝐜𝐭 𝐀𝐭𝐭𝐫𝐢𝐛𝐮𝐭𝐞-𝐕𝐚𝐥𝐮𝐞 𝐈𝐝𝐞𝐧𝐭𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧", has been officially accepted at the prestigious KDD 2025 (ADS Track), which has a highly 𝐜𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐚𝐜𝐜𝐞𝐩𝐭𝐚𝐧𝐜𝐞 𝐫𝐚𝐭𝐞 𝐨𝐟 𝐣𝐮𝐬𝐭 22%! This paper presents 𝐆𝐞𝐧𝐓𝐨𝐂, a groundbreaking solution developed for IndiaMART InterMESH Limited, tackling a significant challenge in 𝐚𝐭𝐭𝐫𝐢𝐛𝐮𝐭𝐞-𝐯𝐚𝐥𝐮𝐞 𝐞𝐱𝐭𝐫𝐚𝐜𝐭𝐢𝐨𝐧 for e-commerce search and recommendation systems by leveraging 𝐩𝐚𝐫𝐭𝐢𝐚𝐥𝐥𝐲-𝐥𝐚𝐛𝐞𝐥𝐞𝐝 𝐝𝐚𝐭𝐚. It is a novel model that not only excels in attribute-value extraction but also bootstraps the training data to enable the 𝐞𝐟𝐟𝐞𝐜𝐭𝐢𝐯𝐞 𝐭𝐫𝐚𝐢𝐧𝐢𝐧𝐠 𝐨𝐟 𝐨𝐭𝐡𝐞𝐫 𝐟𝐚𝐬𝐭𝐞𝐫 𝐍𝐄𝐑 𝐦𝐨𝐝𝐞𝐥𝐬 .This solution delivers a 20.2% 𝐢𝐦𝐩𝐫𝐨𝐯𝐞𝐦𝐞𝐧𝐭 𝐢𝐧 𝐜𝐨𝐫𝐫𝐞𝐜𝐭 𝐢𝐝𝐞𝐧𝐭𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 𝐰𝐡𝐢𝐥𝐞 𝐦𝐚𝐢𝐧𝐭𝐚𝐢𝐧𝐢𝐧𝐠 𝐚 𝐡𝐢𝐠𝐡 𝐩𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐨𝐟 89.5% A big shoutout to our amazing team—Subhalingam D, Keshav Kolluru, Prof. Mausam(IIT Delhi) and Saurabh Singal—for this incredible achievement! Stay tuned for the release of the camera-ready version soon. #NLP #KDD2025 #EcommerceInnovation #GenToC #AIResearch #MachineLearning #IndiaMART #Teamwork #DataScience

🚀 𝐒𝐞𝐚𝐬𝐨𝐧 2 of "𝐓𝐡𝐞 𝐌𝐨𝐥𝐞𝐜𝐮𝐥𝐞 𝐀𝐈 𝐎𝐝𝐲𝐬𝐬𝐞𝐲: 𝐀 𝐉𝐨𝐮𝐫𝐧𝐞𝐲 𝐢𝐧𝐭𝐨 𝐓𝐨𝐦𝐨𝐫𝐫𝐨𝐰'𝐬 𝐃𝐫𝐮𝐠 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲" 𝐢𝐬 𝐇𝐞𝐫𝐞! 🚀 After the incredible response to Season 1, we're thrilled to dive even deeper into the world of AI-driven drug discovery with Season 2! Join us as we continue to explore our cutting-edge methodologies, innovative products, and global media engagements, all shaping the future of medicine. Stay connected for exclusive insights, breakthrough stories, and a closer look at how Molecule AI is revolutionizing healthcare. 🌍🔬 #MoleculeAIOdyssey #DrugDiscovery #AIinHealthcare #Innovation

🌟 Exciting News! 🌟 We’re thrilled to announce that 𝐌𝐨𝐥𝐞𝐜𝐮𝐥𝐞 𝐀𝐈 has been recognized as an 𝐄𝐦𝐞𝐫𝐠𝐢𝐧𝐠 𝐀𝐈 𝐏𝐨𝐰𝐞𝐫𝐞𝐝 𝐃𝐫𝐮𝐠 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐏𝐥𝐚𝐭𝐟𝐨𝐫𝐦 at the BioSpectrum Asia Excellence Awards 2024! 🎉This honor reflects our commitment to innovation in the life sciences sector. https://lnkd.in/gakMzQXv A big thank you to BioSpectrum Asia for this recognition, and we also extend our warmest congratulations to all the other exceptional winners across various categories: Eppendorf , Cytiva , West Pharmaceutical Services, Catalent Pharma Solutions, Medidata Solutions GenScript, Ardor Biomed India PVT LTD, Oliver Healthcare Packaging, and Asia Pacific Medical Technology Association (APACMed). Together, we’re advancing the life sciences field and building a sustainable bioeconomy across Asia. 🌏💼 See you at the awards in Singapore on December 6th for a night of celebration and inspiration! #BioSpectrumAwards #MoleculeAI #LifeSciences #Innovation #Biomanufacturing #SustainableBioeconomy

𝐈𝐬 𝐀𝐈-𝐠𝐮𝐢𝐝𝐞𝐝 𝐛𝐢𝐨𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐚𝐫𝐨𝐮𝐧𝐝 𝐭𝐡𝐞 𝐜𝐨𝐫𝐧𝐞𝐫? 🌏✨ Explore the answer to this with Molecule AI, in our October edition of the newsletter! The APAC region is leading the way with cutting-edge facilities and innovative strategies. From AI-driven efficiencies to sustainable practices, discover how nations like India, China, and Singapore are transforming the production of lifesaving biologics and therapies. Don’t miss the insights into the trends and technologies shaping the next era of healthcare! 🚀🔬 #Biomanufacturing #Innovation #MoleculeAI

𝐖𝐞𝐥𝐜𝐨𝐦𝐞 𝐭𝐨 "𝐓𝐡𝐞 𝐌𝐨𝐥𝐞𝐜𝐮𝐥𝐞 𝐀𝐈 𝐎𝐝𝐲𝐬𝐬𝐞𝐲" 𝑰𝒏 𝒕𝒉𝒆 𝒑𝒓𝒆𝒗𝒊𝒐𝒖𝒔 𝒑𝒐𝒔𝒕 𝒘𝒆 𝒍𝒆𝒂𝒓𝒏𝒕 𝒂𝒃𝒐𝒖𝒕 𝒉𝒐𝒘 𝑴𝑨𝑰-𝑳𝒊𝒈 𝑻𝒂𝒓𝒈 𝒔𝒐𝒍𝒗𝒆𝒔 𝒕𝒉𝒆 𝒑𝒓𝒐𝒃𝒍𝒆𝒎 𝒐𝒇 𝒐𝒇𝒇 𝒕𝒂𝒓𝒈𝒆𝒕 𝒕𝒐𝒙𝒊𝒄𝒊𝒕𝒚: Molecule GEN’s 𝐋𝐢𝐠-𝐓𝐚𝐫𝐠 module predicts 𝐩𝐨𝐭𝐞𝐧𝐭𝐢𝐚𝐥 𝐚𝐥𝐭𝐞𝐫𝐧𝐚𝐭𝐞 𝐭𝐚𝐫𝐠𝐞𝐭𝐬 𝐨𝐟 𝐬𝐦𝐚𝐥𝐥-𝐦𝐨𝐥𝐞𝐜𝐮𝐥𝐞 𝐝𝐫𝐮𝐠𝐬. It searches a 𝐜𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐝𝐚𝐭𝐚𝐛𝐚𝐬𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐞𝐧𝐭𝐢𝐫𝐞 𝐡𝐮𝐦𝐚𝐧 𝐩𝐫𝐨𝐭𝐞𝐨𝐦𝐞 and identifies 𝐩𝐫𝐨𝐭𝐞𝐢𝐧 𝐜𝐚𝐯𝐢𝐭𝐢𝐞𝐬 𝐫𝐞𝐬𝐞𝐦𝐛𝐥𝐢𝐧𝐠 𝐭𝐡𝐞 𝐭𝐚𝐫𝐠𝐞𝐭 𝐩𝐫𝐨𝐭𝐞𝐢𝐧'𝐬 𝐛𝐢𝐧𝐝𝐢𝐧𝐠 𝐜𝐚𝐯𝐢𝐭𝐲. While computing the similarity measure, we consider both the 𝐬𝐡𝐚𝐩𝐞 𝐚𝐧𝐝 𝐜𝐡𝐞𝐦𝐢𝐜𝐚𝐥 𝐧𝐚𝐭𝐮𝐫𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐛𝐢𝐧𝐝𝐢𝐧𝐠 𝐜𝐚𝐯𝐢𝐭𝐲. The model also provides the binding affinity for the ligand against those proteins that it estimates more likely to bind against. 𝐓𝐡𝐢𝐬 𝐩𝐫𝐨𝐯𝐢𝐝𝐞𝐬 𝐯𝐚𝐥𝐮𝐚𝐛𝐥𝐞 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐢𝐧𝐭𝐨 𝐩𝐨𝐬𝐬𝐢𝐛𝐥𝐞 𝐚𝐥𝐭𝐞𝐫𝐧𝐚𝐭𝐞-𝐭𝐚𝐫𝐠𝐞𝐭 𝐢𝐧𝐭𝐞𝐫𝐚𝐜𝐭𝐢𝐨𝐧𝐬, aiding, for example, in the experimental validation and optimisation of lead compounds to minimise off-target interactions. 𝑰𝒏 𝒕𝒉𝒊𝒔 𝒑𝒐𝒔𝒕 𝒘𝒆 𝒘𝒊𝒍𝒍 𝒍𝒆𝒂𝒓𝒏 𝒂𝒃𝒐𝒖𝒕 𝒂 𝒄𝒂𝒔𝒆 𝒔𝒕𝒖𝒅𝒚 𝒊𝒏𝒗𝒐𝒍𝒗𝒊𝒏𝒈 𝒕𝒉𝒆 𝒃𝒆𝒔𝒑𝒐𝒌𝒆 𝒂𝒏𝒂𝒍𝒐𝒈𝒖𝒆𝒔 𝒐𝒇 𝒂 𝒍𝒆𝒂𝒅𝒊𝒏𝒈 𝒂𝒏𝒂𝒆𝒔𝒕𝒉𝒆𝒕𝒊𝒄 𝒎𝒐𝒍𝒆𝒄𝒖𝒍𝒆. 𝐊𝐞𝐭𝐚𝐦𝐢𝐧𝐞 is widely used in medical settings due to its anaesthetic, analgesic, and antidepressant properties. However, it has 𝐡𝐚𝐥𝐥𝐮𝐜𝐢𝐧𝐨𝐠𝐞𝐧𝐢𝐜 𝐚𝐧𝐝 𝐨𝐭𝐡𝐞𝐫 𝐩𝐬𝐲𝐜𝐡𝐢𝐚𝐭𝐫𝐢𝐜 𝐬𝐢𝐝𝐞 𝐞𝐟𝐟𝐞𝐜𝐭𝐬, which have led to its abuse as a recreational drug. A substitute for ketamine that preserves its medical effects, while 𝐦𝐢𝐧𝐢𝐦𝐢𝐬𝐢𝐧𝐠 𝐭𝐡𝐞 𝐮𝐧𝐝𝐞𝐬𝐢𝐫𝐚𝐛𝐥𝐞 𝐬𝐢𝐝𝐞 𝐞𝐟𝐟𝐞𝐜𝐭𝐬 would represent a significant medical advancement with a very large market demand. One of the major targets of ketamine action is believed to be the 𝐍-𝐦𝐞𝐭𝐡𝐲𝐥 𝐃-𝐚𝐬𝐩𝐚𝐫𝐭𝐚𝐭𝐞 𝐫𝐞𝐜𝐞𝐩𝐭𝐨𝐫 (𝐍𝐌𝐃𝐀𝐑). We have used our 𝐌𝐨𝐥𝐞𝐜𝐮𝐥𝐞 𝐆𝐄𝐍 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 for the de novo design of 𝐍𝐌𝐃𝐀𝐑 𝐛𝐢𝐧𝐝𝐞𝐫𝐬 with druglike properties and a safe 𝐀𝐃𝐌𝐄𝐓 𝐩𝐫𝐨𝐟𝐢𝐥𝐞. A clinical research team in Waikato, New Zealand, is testing our designed molecules through brain-slice experiments on rodents. Below are some properties of representative 𝐍𝐌𝐃𝐀𝐑 binder molecules generated by us, along with those for ketamine as the reference molecule. 𝐖𝐢𝐭𝐡 𝐭𝐡𝐢𝐬 𝐰𝐞 𝐰𝐫𝐚𝐩 𝐮𝐩 𝐭𝐡𝐞 𝐒𝐞𝐚𝐬𝐨𝐧 1 𝐨𝐟 𝐌𝐨𝐥𝐞𝐜𝐮𝐥𝐞 𝐀𝐈 𝐎𝐝𝐲𝐬𝐬𝐞𝐲: 𝐀 𝐣𝐨𝐮𝐫𝐧𝐞𝐲 𝐭𝐡𝐫𝐨𝐮𝐠𝐡 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧, 𝐛𝐫𝐞𝐚𝐤𝐭𝐡𝐫𝐨𝐮𝐠𝐡𝐬, 𝐚𝐧𝐝 𝐭𝐡𝐞 𝐟𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐀𝐈-𝐝𝐫𝐢𝐯𝐞𝐧 𝐝𝐫𝐮𝐠 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲. 𝐒𝐭𝐚𝐲 𝐭𝐮𝐧𝐞𝐝 𝐚𝐬 𝐰𝐞 𝐜𝐨𝐧𝐭𝐢𝐧𝐮𝐞 𝐭𝐨 𝐩𝐮𝐬𝐡 𝐛𝐨𝐮𝐧𝐝𝐚𝐫𝐢𝐞𝐬 𝐢𝐧 𝐒𝐞𝐚𝐬𝐨𝐧 2! #MoleculeAIOdyssey #AIDrugDiscovery #InnovatingTheFuture"

🙏 A Heartfelt Thank You from Molecule AI! 🌿 It's been a week since Global Bio India 2024, and we’re still buzzing with excitement from the incredible experience at the event. We want to extend our deepest thanks to everyone who visited us, engaged in discussions, and showed such genuine interest in our AI-driven platform, MoleculeGEN. Your enthusiasm and curiosity about how AI can revolutionize drug discovery truly made the event unforgettable. A special shoutout to the organizers of Global Bio India 2024: Biotechnology Industry Research Assistance Council (BIRAC) and Department of Biotechnology, for creating such an impactful platform for innovation, collaboration, and knowledge-sharing. The event provided us with the opportunity to connect with brilliant minds and share our vision for the future of healthcare. We’re excited to continue building on the momentum of the event and look forward to future collaborations and breakthroughs! #GlobalBioIndia2024 #Moleculeai #ThankYou #AIinBiotech #DrugDiscovery #InnovationInHealthcare #FutureOfHealth #ai #pharmacy #machinelearning

🌟 Welcome to Day 2 of Global Bio India 2024! 🌟 We’re back for Day 2 at POD no. 161, Hall no. 5, Pragati Maidan, New Delhi, and ready for another exciting day of biotech innovation! 🎯 Visiting Hours: 3:30 to 6 PM 👥 Who’s here? Come meet Mr. Vishay Rawar and Dr. Sameer Agarwal, PhD, representing Molecule ai, and learn about our game-changing AI platform, MoleculeGEN. 💡 Whether you’re curious about how AI is transforming drug discovery or want to see how MoleculeGEN can accelerate R&D, Day 2 is your chance to dive deep into the future of healthcare. Let’s continue exploring biotech breakthroughs together! #GlobalBioIndia2024 #Moleculeai #Day2 #AIinBiotech #DrugDiscovery #InnovationInHealthcare #FutureOfHealth #AI #pharmacy #computatuionalchemistry

🌟 Day 1 Highlights from Global Bio India 2024 🌟 Day 1 at Global Bio-India 2024 was a great success! We had an enthusiastic crowd visiting us at POD no. 161, eager to learn more about our AI-powered platform, MoleculeGEN. 💡 Key Takeaways: Attendees were particularly interested in how MoleculeGEN works and its potential to transform the drug discovery process. We discussed the platform’s ability to: Accelerate drug discovery by predicting new molecular structures faster than traditional methods. Reduce costs through highly efficient computational models. Improve accuracy in identifying viable drug candidates with enhanced AI-driven data analysis. 👥 Visitors were excited about the prospect of MoleculeGEN revolutionizing the pharmaceutical industry by reducing timelines, improving the success rate of new therapies, and ultimately reshaping healthcare innovation. As Day 1 comes to a close, we look forward to continuing these discussions and sharing more insights with industry experts and innovators. #MoleculeGEN #AIinHealthcare #DrugDiscovery #InnovationInBiotech #GlobalBioIndia2024